Theravance Biopharma (NASDAQ:TBPH) Given New $17.00 Price Target at B. Riley Financial

Theravance Biopharma (NASDAQ:TBPH) had its price objective raised by research analysts at B. Riley Financial from $14.00 to $17.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. B. Riley Financial’s price objective would indicate a potential upside of 3.58% from the stock’s previous close.

Several other analysts also recently commented on TBPH. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Monday. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, March 24th. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. HC Wainwright upped their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, TD Cowen increased their price target on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.83.

Theravance Biopharma Stock Up 1.9%

TBPH traded up $0.31 on Tuesday, reaching $16.41. The company had a trading volume of 170,583 shares, compared to its average volume of 617,325. Theravance Biopharma has a 1 year low of $8.09 and a 1 year high of $21.03. The stock has a market capitalization of $845.11 million, a PE ratio of 8.09 and a beta of 0.17. The stock has a 50-day moving average price of $16.97 and a 200-day moving average price of $17.00.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of TBPH. Arrowstreet Capital Limited Partnership acquired a new position in Theravance Biopharma in the third quarter valued at $10,611,000. Assenagon Asset Management S.A. increased its stake in Theravance Biopharma by 1,629.4% during the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after acquiring an additional 390,735 shares during the last quarter. Pacer Advisors Inc. purchased a new position in shares of Theravance Biopharma in the 4th quarter worth about $6,342,000. Hillsdale Investment Management Inc. acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $4,536,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after purchasing an additional 273,288 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.